Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.04 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

ico therapeutics inc (ICOTF) Key Developments

iCo Therapeutics Announces Earnings Results for the Second Quarter Ended June 30, 2015

iCo Therapeutics announced earnings results for the second quarter ended June 30, 2015. For the quarter, the company incurred a total comprehensive loss of $738,607 or loss per share of $0.01 compared to total comprehensive loss of $2,982,109 or loss per share of $0.04 for the quarter ended June 30, 2014, representing a reduced loss of $2,243,502. This decrease is primarily a result of the both the sale and change in value of investment in Immune Therapeutics Inc., as well completion of iCO-007 iDEAL trial.

iCo Therapeutics Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

iCo Therapeutics Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company incurred a total comprehensive loss of $252,397 (loss per share of $0.00), compared to total comprehensive earnings of $1,365,068 (earnings per share of $0.02) for the quarter ended March 31, 2014, representing an increased loss of $1,617,465. The increase is primarily a result of changes related to holdings in Immune Pharmaceuticals Inc.

iCo Therapeutics Inc. Reports Financial Results for the Year Ended December 31, 2014

iCo Therapeutics Inc. reported financial results for the year ended December 31, 2014. The company incurred a total comprehensive loss of CAD,079,657 for the year ended December 31, 2014 compared to a total loss of CAD 5,918,965 for the year ended 2013, representing a decrease of CAD 3,839,308. The decrease in its net and comprehensive loss was principally caused by a reduction of clinical trial costs associated with the iDEAL study.

iCo Therapeutics Inc., Annual General Meeting, Jun 26, 2015

iCo Therapeutics Inc., Annual General Meeting, Jun 26, 2015. Location: 595 Burrard Street, Suite 2600.

iCo Therapeutics Seeks Acquisitions

iCo Therapeutics Inc. (TSXV:ICO) is looking for acquisitions. Andrew Rae, President and Chief Executive Officer of iCo Therapeutics states, "We remain committed to our oral Amphotericin B clinical study plans and continue to assess complimentary assets which the Company may consider in-licensing or acquiring."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICOTF:US $0.04 USD 0.00

ICOTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICOTF.
View Industry Companies
 

Industry Analysis

ICOTF

Industry Average

Valuation ICOTF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICO THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.